Vanda Pharmaceuticals (VNDA)

• Market cap: $254M
• 1 day: -1.80%
• 5 days: -5.22%
• 1 month: -7.82%
• 3 months: -8.02%
• 6 months: -29.90%
• Year to date: -9.54%
• 1 year: 15.96%
• 5 years: -71.14%
• 10 years: -63.82%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Employees: 203

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

501% more call options, than puts

Call options by funds: $1.57M | Put options by funds: $261K

24% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 21

2% more funds holding

Funds holding: 148 [Q2] → 151 (+3) [Q3]

3.1% less ownership

Funds ownership: 78.63% [Q2] → 75.53% (-3.1%) [Q3]

17% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 54

20% less capital invested

Capital invested by funds: $259M [Q2] → $206M (-$52.2M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $18 313% upside
• Avg. target: $18 313% upside
• High target: $18 313% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 119 / 312 met price target

313% upside $18

Buy Reiterated

23 Dec 2024